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  A simple and economic synthesis of 3,4-dihydropyrimidin-2(1H)-ones using pyridinium   
triflate as catalyst under microwave condition was attempted with an easy work-up protocol. 
Further tetrazolo [1,5-a] pyrimidine-6-carboxylates were synthesized by three-component 
coupling reaction of β-ketoesters with a mixture of aromatic aldehyde and 5-aminotetrazole.  
The products were well characterized with IR, NMR (1H and 13C NMR) and mass 
spectrometry.  
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1.  Introduction 
 
   Three component coupling reactions are long known as an efficient and simple method for the 
synthesis of dihydropyridines
1, dihydropyrimidine derviatives
2 and tetrazolopyrimidines
3.
 Biginelli 
compounds and its analogues have wide applications because of their pharmaceutical and therapeutic 
properties
4. Though research on Biginelli reaction is time tested, still active molecules are emerging 
with dihydropyrimidine core because of their medicinal importance as antihypertensive agents and 
calcium channel blockers
5. Further, monastrol with dihydropyrimidine core moiety is much explored 
owing to its wide application as a cell-permeable small molecule inhibitor of the mitotic kinesin, 
Eg5
6. Several of the marine alkaloids also found to contain the dihydropyrimidine core unit by nature 
and were found to show interesting biological activities such as antiviral, antibacterial and anti-
inflammatory activity 
7, 8. Thus the synthesis of the dihydropyrimidine core unit gains much   28
importance. Purine derivatives which are well-known for its wide range of biological activities, such 
as antimicrobial activity
9, fungicidal activity
3, antihypertensive
10, K(ATP) channel opening
11, central 
nervous system stimulating
12 etc., has interestingly the fundamental  dihydropyrimidine core. 
 
   There exist a number of conditions for the synthesis of 3,4-dihydropyrimidin-2(1H)-ones using 
Lewis acid catalysts such as InCl3
13, Cu(OTf)2
14, CF3COONH4 
15, organo catalyst 
16, Trifluoro Acetic 
Acid 
17, Metal triflimide 
18,
 acid catalyst 
19 etc. Tetrazolopyrimidines were synthesised using iodine
20, 
mineral acid 
21, sulfamic acid 
22 and strontium chloride hexahydrate 
23.
 Our interest was to further 
explore the interesting dihydropyrimidine core and its synthesis. With an equal interest towards the 
synthesis of tetrazolopyrimidines, which still remain unexplored in terms of its synthesis and 
biological activity. According to our extensive literature survey we understood that the available 
synthetic protocols include high temperatures, prolonged reaction time, drastic reaction conditions, 
low yields and the use of often expensive acid catalysts. In order to develop a simpler protocol for the 
synthesis of these biologically important compounds, we optimized and herein report pyridinium 
trifluoroacetate catalysed synthetic method. Further to our interest the catalyst is readily available 
from commercial sources and is an economic catalyst.  
2. Results and Discussion 
 
   Because of its favourable acidity, pyridinium triflate catalyses biginelli three component coupling 
reaction between aldehyde, urea or 5-amino tetrazole and the β-keto ester. Further the microwave 
irradiation at 90
oC effectively reduces the reaction completion time from 4 hours (reflux) to for 40 
min
 with good to excellent yields (Scheme 1). The method is worked and well optimized for both 
aromatic aldehydes and functional hetero-aromatic aldehydes. Wide range of aldehydes with electron 
withdrawing and electron donating substituents are experimented under the pyridinium triflate 
catalysed reaction condition. 
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Scheme. 1. Representative triflate salt (TFA: pyridine) mediated synthesis of dihydropyrimidines and 
Tetrazolo pyrimidines 
 
   It was observed longer reaction time in the case of the electron withdrawing substituent in the 
aldehyde phenyl ring that further affected the yield (5g in Table  1) of product. The positive 
mesomeric effect of p-Chloro substituent enhanced the reaction yield (5e) with the reduction in the 
reaction completion time. The steric hindrance at ortho position reduced the reaction yield (5f). The 
nature and position of the substituents in the aromatic aldehydes affected the course of the reaction 
and product yield.  
 
   Heteroaromatic aldehydes were also undergone the biginelli reaction with the pyridinium triflate 
mediated protocol so as to generalize the reaction condition for all the aromatic systems. Compared to 
the aromatic systems it was observed that the heteroaromatic systems produced less yield. R. Chandran  / Current Chemistry Letters 1 (2012) 
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Table 1  
General synthesis of pyridinium triflate mediated dihydropyrimidines 
Compound R1 R 2  X  Time (min)  Yield (%)
a  Mp (
oC) 
5a  phenyl  CH3  O  10  98  201-203 
5b Phenyl  CH3 S 15  83  207-208 
5c  Phenyl  H  O  14  96  190-191 
5d 3-Methoxy  phenyl  CH3 O 38  90  220-222 
5e  4-Chloro phenyl  H  S  15  97  138-139 
5f 2-hydroxy-5-t- butyl phenyl  CH3 O 35  70  222-225 
5g  3,5-Bis trifluoromethyl phenyl  CH3  O  40  65  209-210 
5h 2-Thienyl  CH3 O 28  75  204-205 
5i  2-Imidazolyl  CH3  O  30  70  249-251 
5j 2-Pyridyl  CH3 O 32  84  180-182 
5k  2-Thiazolyl  CH3 O  38  60  211-213 
 a Isolated yield 
 b All the target molecules were characterized with IR, LCMS, 
1H NMR, 
13C NMR. 
 
   Similar trend with respect to the substituents in the aldehydic groups was observed during the 
synthesis of tetrazolopyrimidines also (Table 2). Thus the versatility of pyridinium trifluoroacetate 
mediated route was clear from the good to excellent yields of dihydropyrimidines and 
tetrazolopyrimidines under microwave assisted reaction conditions. Further we have achieved the 
synthesis of the title compounds with commercially available and economic catalyst with reduced 
reaction times. 
 
Table 2  
General synthesis of pyridinium triflate mediated tetrazolo [1,5a] pyrimidines. 
Compound R1 R 2  Time (min)  Yield (%)
a,b  Mp (
oC) 
6a  Phenyl  CH3  25  98  196-198 
6b 3-Methoxy  phenyl  H 28 83  184-185 
6c  3-phenyl propinal  CH3  30  95  165-166 
6d 2-Fluoro    CH3 30  89  180-183 
6e  2-Pyridyl  CH3  27  90  256-257 
6f 3-Thiophenyl  CH3 35  85  197-198 
6g  3-Thiophenyl  H  25  89  183-184 
6h 5-Br-2-thiophenyl  CH3 35  68  180-181 
6i  2-Furyl  CH3  34  75  189-192 
6j phenyl
c dimedone  25  93  268-273 
6k  4-biphenyl 
c  dimedone  20  95  287-288 
 a Isolated yield, 
b All the target molecules were characterized with IR, LCMS, 
1H NMR, 
13C NMR. 
c All reactions  were carried out using Dimedone instead of Ethyl aceto acetate. 
 
   We have compared the reactivity of the pyridinium triflate catalysed biginelli reaction with the 
ammonium trifluoroacetate catalysed condition. It was observed from the comparison experiments 
(Table 3) that the pyridinium catalyst has improved the yield of the reaction when compared to other 
catalyst.  
 
Table 3   
Catalyst optimization for the synthesis of 5a, 6a under solvent- media 
Entry Triflate  salt 
a,b  Temp (°C)  Time (min)  Yield (%)
 
1 CF3COONH4  
c 90  40  89  (5a) & 85 (6a) 
2  Pyridinium    trifluoroacetate  90  25  95 (5a) & 93 (6a) 
a All the reaction were carried out in 1:1 ratio.  
b All the reaction were carried out in both acetonitrile and ethanol. 
c Ammonium Trifluoroacetate   30
3. Conclusions  
 
   A new method of synthesis for dihydropyrimidines and tetrazolopyrimidines was accomplished 
mediated by pyridinium triflate catalyst. In general the reaction time for the synthesis has been 
reduced with the utility of microwave assisted synthesis. The evaluation of anticancer and antioxidant 
activity of the synthesized novel tetrazolopyrimidines will be of our future interest. 
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4. Experimental 
 
4.1 Materials and Methods 
 
   Common reagents and solvents were purchased from commercial sources.  
1H NMR (300 or 400 
MHz) and 
13C NMR (75 or 100 MHz) spectra were recorded in DMSO-d6  on a Bruker DPX 300 and 
400 MHz spectrometer with chemical shifts being reported in parts per million (δ) relative to internal 
standard tetramethylsilane.  IR spectra were obtained as mineral- oil mulls on a Spekord N80 
spectrophotometer in the frequency of absorption (cm
-1). Low resolution mass spectra were recorded 
at ionizing voltage (eV) by electron impact. Melting points were determined with Buchi melting B-
545. 
 
4.2 General procedure 
 
   A mixture of aldehyde (1 mmol), β-diketo ester/ dimedone (1 mmol), Urea (1.5 mmol) / thiourea 
(1.5 mmol) / 5-amino tetrazole (1 mmol) and pyridinium Trifluoroacetate (0.5 mmol) was taken in a 
microwave vial and irradiated at 90
oC for 30 to 40min. After cooling, solid formed was filtered and 
washed with cold water (2 ×10ml) followed by diethyl ether, if necessary recrystallised from ethanol 
or ethyl acetate to afford pure product. 
 
 
4.3 Physical and Spectral Data 
Compound- 5b: 
1H NMR (300 MHz, DMSO-d6): δ 10.33 (s, 1H), 9.65 (brs, 1H), 7.36-7.19 (m, 5H), 
5.16 (d, 1H, J = 3.6 Hz), 4.03 (q, 2H), 2.28 (s, 3H), 1.10 (t, 3H). 
13C NMR (75 MHz, DMSO-d6): 
174.7, 165.6, 145.5, 143.9, 129.0, 128.1, 126.8, 101.2, 60.0, 54.5, 17.6, 14.5. IR (KBr): 3328, 3174, 
3106, 2982, 1671, 1573, 1467, 1422, 1327, 1197, 1117, 1026, 722 cm
-1. LC/MS:m/z  277 (M+H
+). 
 
Compound- 5c: 
1H NMR (300 MHz, DMSO-d6): δ 9.20 (s, 1H), 7.74 (brs, 1H), 7.31-7.20 (m, 5H), 
5.13 (d, 1H, J = 3.42 Hz), 3.51 (s, 3H), 2.23 (s, 3H). 
13C NMR (75 MHz, DMSO-d6): 166.3, 152.6, 
149.1, 145.1, 128.9, 127.7, 126.6, 99.5, 54.2, 51.2, 18.3. IR (KBr): 3446, 3333, 3222, 2950, 1696, 
1667, 1437, 1349, 1239, 1094, 792, 698, 520, 458 cm
-1 LC/MS:m/z  247 (M+H
+). 
 
Compound-5d : 
1H NMR (300 MHz, DMSO-d6): δ 9.19 (s, 1H), 7.73 (brs, 1H), 7.23 (t, 1H), 6.81-
6.76 (m, 3H), 5.10 (s, 1H), 3.99 (q, 2H, J = 7Hz), 3.70 (s, 3H), 2.22 (s, 3H), 1.11 (t, 3H, J = 7.08 
Hz). 
13C NMR (75 MHz, DMSO-d6): δ 165.8, 159.7, 152.6, 148.9, 146.8, 130.0, 118.7, 112.8, 112.6, 
99.6, 59.7, 55.4, 54.2, 18.2, 14.6. IR (KBr): 3240, 3104, 2931, 1704, 1649, 1330, 1091 cm
-1. LC/MS: 
m/z  291 (M+H
+). 
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Compound-5e : 
1H NMR (300 MHz, DMSO-d6): δ 10.40 (s, 1H), 9.68 (s, 1H), 7.43-7.40 (d, 2H, J 
=9 Hz) 7.23-7.20 (d, 2H, J =9 Hz), 5.16 (s, 1H), 3.54 (s, 3H), 2.28 (s, 3H). 
13C NMR (75 MHz, 
DMSO-d6): δ  174.7, 166.0, 146.1, 142.6, 132.8, 129.1, 128.7, 100.5, 53.8, 51.6, 17.7. IR (KBr): 
3313, 3169, 2995, 2947, 1715, 1570, 1190, 1113, 827 cm
-1 LC/MS:m/z  297  (M+H
+). 
 
Compound-5f : 
1H NMR (300 MHz, DMSO-d6): δ 9.33 (s, 1H), 9.07 (s, 1H), 7.04-7.00 (m, 3H), 
6.70-6.67 (d, 1H, J = 8.34 Hz), 5.37 (brs, 1H), 3.93-3.89 (q, 2H, J = 7 Hz), 2.23 (s, 1H), 1.17 (s, 9H), 
1.05-1.00 (t, 3H, J = 7 Hz). 
13C NMR (75 MHz, DMSO-d6): δ 166.0, 152.9, 152.7, 148.7, 140.9, 
129.4, 125.3, 124.5, 115.5, 98.2, 59.3, 50.8, 33.9, 31.8, 18.1, 14.6. IR (KBr): 3382, 3283, 2958, 1678, 
1629, 1219, 1003, 876, 605 cm
-1 LC/MS: m/z 331 (M-H
+). 
 
Compound-5g : 
1H NMR (300 MHz, DMSO-d6): δ 9.41 (s, 1H), 80.5 (s, 1H), 7.91-7.84 (m, 3H), 
5.37 (brs, 1H), 3.99-3.96 (q, 2H), 2. 26 (s, 3H), 1.07-1.02 (t, 3H). 
13C NMR (75 MHz, DMSO-d6): δ 
165.4, 152.0, 150.3, 148.7, 131.0, 130.7, 127.5, 125.1, 98.3, 59.9, 54.0, 18.3, 14.3. IR (KBr): 3441, 
3321, 1654, 1543, 1275, 1118, 896, 676 cm
-1. LC/MS: m/z 395 (M-H
+). 
 
Compound-5h : 
1H NMR (300 MHz, DMSO-d6): δ 9.33 (brs, 1H), 7.91 (brs, 1H), 7.35 (d, 1H, J = 
4.98 Hz), 6.94-6.88 (m, 2H), 5.26 (s, 1H), 4.08 (q, 2H, J = 7.08 Hz), 2.20 (s, 3H), 1.17 (t, 3H, J = 
7.11 Hz). 
13C NMR (75 MHz, DMSO-d6): 165.5, 160.0, 152.7, 149.2, 127.1, 125.1, 123.9, 100.3, 
59.8, 49.8, 18.1, 14.6. IR (KBr): 3446, 3336, 2983, 1628, 1457, 1315, 1231, 1157, 1025, 710, 556 
cm
-1 LC/MS:m/z  267.1 (M+H
+). 
 
Compound-5i : 
1H NMR (300 MHz, DMSO-d6): δ 11.2 (brs, 1H), 8.96 (s, 1H), 6.72 (s, 2H), 4.93 (s, 
1H), 4.05-.3.98 (q, 2H, J = 7 Hz), 2.19 (s, 3H), 1.14-1.09 (t, 3H, J = 7 Hz). IR (KBr): 3358, 3165, 
3039, 2980, 2900, 2810, 1654, 1511, 1207, 1016, 818, 657 cm
-1 LC/MS:m/z 251 (M+H
+). 
 
Compound-5j : 
1H NMR (300 MHz, DMSO-d6): δ 9.25 (s, 1H), 8.59-8.57 (d, 1H, J = 4.5 Hz), 7.96-
7.91 (t, 1H, J = 7.6 Hz), 7.70 (s, 1H), 7.44-7.40 (m, 2H), 5.28 (brs, 1H), 3.97-3.91 (q, 2H, J = 7 Hz), 
2.22 (s, 3H), 1.09-1.01 (t, 3H, J = 7 Hz). 
13C NMR (75 MHz, DMSO-d6): δ 165.6, 161.7, 152.3, 
149.9, 147.8, 139.5, 123.9, 122.4, 97.6, 59.6, 55.6, 18.4, 14.5. IR (KBr): 3209, 3081, 2947, 1698, 
1650, 1068, 814 cm
-1  LC/MS: m/z 262  (M+H
+). 
 
Compound- 5k : 
1H NMR (300 MHz, DMSO-d6): δ 9.39 (brs, 1H), 7.99 (brs, 1H), 7.72-7.71 (d, 1H, 
J = 3.21 Hz), 7.62-7.61 (d, 1H, J = 3.21 Hz), 5.47 (brs, 1H), 4.08-.4.01 (q, 2H, J = 7 Hz), 2.22 (s, 
3H), 1.15-1.09 (t, 3H, J = 7 Hz). 
13C NMR (75 MHz, DMSO-d6): δ 173.3, 165.3, 152.5, 150.4, 142.9, 
120.7, 98.5, 59.9, 52.0, 18.2, 14.6. IR (KBr): 3204, 3074, 2855, 1692, 1632, 1214, 1088, 944, 752 
cm
-1 LC/MS: m/z 268 (M+H
+). 
 
Compound- 6a :
1H NMR (300 MHz, DMSO-d6): δ 11.33 (s, 1H), 7.34-7.28 (m, 5H), 6.64 (s, 1H), 
3.97-3.92 (q, 2H, J = 7 Hz), 2.44 (s, 3H), 1.02 (t, 3H, J = 7 Hz). 
13C NMR (100 MHz, DMSO-d6): 
164.5, 148.4, 146.6, 140.9, 128.7, 128.5, 127.2, 97.7, 59.6, 58.7, 18.4, 13.8. IR (KBr): 3224, 3162, 
3053, 2986, 2946, 1696, 1656, 1569, 1299 1230, 1099, 1019, 655 cm
-1. LC/MS:m/z  286 (M+H
+). 
 
Compound- 6b: 
1H NMR (400 MHz, DMSO-d6): δ 14.33 (brs, 1H), 11.31 (1H, s), 7.28-7.24 (m, 
1H), 6.89-6.81 (m, 3H), 6.64 (1H, s), 6.48 (2H, s), 3.73 (s, 3H), 3.53 (s, 3H), 2.49 (s, 3H). 
13C NMR 
(100 MHz, DMSO-d6): 165.2, 159.3, 156.4, 148.5, 146.8, 142.3, 130.1, 119, 113.4, 113.3, 97.5, 58.5, 
55.1, 51.1, 18.5. IR (KBr): 3474, 3335, 3260, 3187, 2950, 1661, 1575, 1431, 1298, 1158, 1034, 772 
cm
-1.LC/MS: m/z 301 (M+H
+). 
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Compound- 6c: 
1H NMR (300 MHz, DMSO-d6): δ 11.3 (brs,1H), 7.26-7.10 (m, 5H), 6.42 (s, 1H), 
5.62 (1H, s), 4.12-4.05 (q, 2H, J = 7 Hz), 2.48 (m, 2H), 2.32 (3H, s), 2.09 (2H, m), 1.16 (t, 3H, J = 7 
Hz). 
13C NMR (100 MHz, DMSO-d6): 165.2, 149.7, 148, 140.7, 128.7, 128.6, 126.4, 97.1, 60.2, 55.2, 
37.7, 30.8, 18.9, 14.5. IR (KBr): 3384, 3184, 3057, 2980, 2854, 1698, 1562, 1451, 1220, 1097, 698 
cm
-1. LC/MS:m/z  312 (M-H
+). 
 
Compound- 6d : 
1H NMR (300MHz, DMSO-d6): δ 1.00 (3H, t, J=7.08 Hz), 2.50 (3H, s,), 3.94 (2H, 
q, J=7.08 Hz), 6.88 (1H, s), 7.21-7.16 (2H, m), 7.40-7.34 (2H, m), 11.36 (1H, brs, NH).
13C NMR: (75 
MHz, DMSO-d6): δ 14.2, 18.9, 53.8, 60.1, 96.7, 116, 116.2, 125.2, 125.3, 128.2, 128.3, 130.1, 130.2, 
131.2, 131.3, 147.7, 148.9, 158.9, 161.4, 164.8.IR (KBr): 3227, 3057, 2986, 2945,  1657, 1569, 1491, 
1333, 1270, 1126, 1021, 855, 754.cm
-1. LC/ MS:m/z  303 (M+H
+). 
 
Compound- 6e : 
1H NMR (300 MHz, DMSO-d6): δ 11.2 (brs, 1H), 8.42-8.41 (m, 1H), 7.81 (t, 1H), 
7.59-7.56 (1H, t, J = 7.6 Hz),7.24 (1H, t), 6.74 (1H, s), 3.97-3.92 (q, 2H, J = 7 Hz), 2.44 (s, 3H), 1.02 
(t, 3H, J = 7 Hz). 
13C NMR (100 MHz, DMSO-d6): 165.1, 158.8, 150.2, 149.6, 147.6, 137.3, 124.1, 
123, 97.5, 60.1, 60, 19, 14.3.  IR (KBr): 3179, 3052, 2946, 1702, 1566, 1277, 1224, 1068, 755 cm
-1. 
LC/MS: m/z 287 (M+H
+). 
 
Compound- 6f: 
1H NMR (400 MHz, DMSO-d6): δ 11.3 (brs, 1H), 7.49-7.41 (m, 1H), 7.25-7.1 (m, 
3H), 6.70 (1H, s), 4.1- 3.8 (2H, m, J = 7 Hz), 2.51 (s, 3H), 1.02 (t, 3H, J = 7 Hz). 
13C NMR (100 
MHz, DMSO-d6): 164.9, 163.7, 161.3, 148.7, 147.6, 144.1, 144, 131.3, 131.2, 123.9, 123.8, 115.9, 
115.7, 114.8, 114.6, 97.5, 60.1, 58.6, 18.9, 14.2.  IR (KBr): 3179, 3052, 2946, 1702, 1566, 1277, 
1224, 1068, 755 cm
-1. LC/MS:m/z  290 (M-H
+). 
 
Compound- 6g: 
1H NMR (400 MHz, DMSO-d6): δ 11.3 (brs, 1H), 7.48-7.45 (m, 2H), 6.96-6.94 (d, 
1H), 6.78 (1H, s), 3.57 (3H, s), 2.49 (s, 3H). 
13C NMR (100 MHz, DMSO-d6): 165.1, 148.5, 146.7, 
141.4, 127.3, 126, 123.8, 97.4, 53.6, 51.1, 18.4.  IR (KBr): 3163, 3079, 2942, 1710, 577, 1434, 1269, 
1213, 1140, 1065, 763 cm
-1. LC/MS:m/z  276 (M-H
+). 
 
Compound- 6h: 
1H NMR (300 MHz, DMSO-d6): δ 11.5 (brs, 1H), 7.09 (m, 1H), 6.95-6.91 (m, 2H), 
6.44 (1H, s), 4.04 (q, 2H, J = 7 Hz), 2.43(3H, s), 1.08 (t, 3H, J = 7 Hz). 
13C NMR (75 MHz, DMSO-
d6): 164.8, 148.6, 147.9, 146, 130.9, 127.7, 112.5, 97.3, 60.4, 53.9, 18.9, 14.4.  IR (KBr): 3470, 3336, 
3186, 2931, 1642, 1566, 1432, 1297, 1217, 1058, 774.  cm
-1.  LC/MS:m/z 367 (M-2H
+). 
 
Compound- 6i: 
1H NMR (300MHz, DMSO-d6): δ 1.12 (3H, t, J=7.08 Hz). 2.40 (3H, s,), 4.08 (2H, q, 
J=7.08 Hz), 6.30 (1H, s), 6.67 (1H, s), 7.56 (1H, s), 7.69 (1H, s), 11.3 (1H, brs).
13C NMR: (75 MHz, 
DMSO-d6): δ 14.4, 18.8, 51.1, 60.2, 97.4, 109.4, 126.2, 141.1, 144.5, 147.1, 149.1, 165.1. IR (KBr): 
3787, 3157, 3086, 2935, 1707, 1567, 1383, 1273, 1069, 778.cm-1.  LC/MS:m/z  275 (M-H
+). 
 
Compound- 6j: 
1H NMR (300MHz, DMSO-d6): δ 0.98 (3H, s), 1.05 (3H, s), 2.20-2.14 (2H, m), 2.58 
(2H, s), 6.58 (1H, s), 7.31-7.25 (5H, m), 11.6 (1H, s).
13C NMR: (75 MHz, DMSO-d6): δ 27.5, 28.7, 
32.7, 50.3, 57.9, 106.1, 127.6, 128.8, 129.1, 140.9, 148.9, 150.9, 193.5.IR (KBr): 3166, 3058, 2958, 
2930, 1647, 1577, 1364, 1314, 734 cm
-1.LC/MS:m/z  296 (M+H
+). 
 
Compound- 6k : 
1H NMR (300MHz, DMSO-d6): δ 1.1 (6H, s), 2.21-2.09 (2H, m), 2.48 (1H,s), 2.6 
(1H, m), 6.64 (1H, s), 7.61-7.58 (4H, m), 7.43-7.34 (5H, m), 11.6 (1H, s).
13C NMR: (100 MHz, 
DMSO-d6): δ 27.1, 27.8, 28.2, 32.3, 32.4, 41.2, 49.9, 57.2, 105.5, 126.7, 126.9, 127.6, 127.8, 128.9, 
139.5, 140.3, 148.4, 150.6, 193.1.IR (KBr): 3385, 3191, 3048, 2921, 2336, 1644, 1578, 1370, 1051 
cm
-1.LC/MS:m/z  372 (M+H
+). 
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